

**CLAIMS**

1. Use of nicotine or a derivative thereof for producing a drug for continuous or progressive administration of 0.2 mg to 5 mg per day per kilogram of body weight in man, said drug being administered simultaneously with L-DOPA in a dose at least 30% lower than the effective dose when L-DOPA is administered alone.
- 5
2. Use according to claim 1, in which the drug is for the treatment of Parkinson's disease and Tourette's syndrome.
- 10
3. Use according to claim 1 or claim 2, in which the nicotine or derivative thereof is administered with L-DOPA in doses at least 50% lower than effective doses when L-DOPA is administered alone.
- 15
4. Use according to any one of claims 1 to 3, in which the drug also comprises a dopaminergic agonist.
- 5.
- Use according to claim 4, in which the agonist is bromocriptine or biperiden.
- 20
6. Use according to any one of claims 1 to 5, in which the drug is intended for the treatment of neurodegenerative diseases over a period of more than four months.
7. Use according to any one of the preceding claims, in which the drug is in a galenical form for controlled liberation of the active principle.
- 25
8. Use according to claim 7, in which the drug is in the form of a transdermal patch.
9. Use according to claim 7, in which the drug is in the liquid form and administered sub-cutaneously using an extracorporeal pump.
- 30